Evidence map›Paper›PMID 42742767›Full record

ArticleMolecular biology reports2026

Unravelling the role of the non-coding RNAs PVT1/miR-181a in orchestrating IL-23/RORγt and FOXP3/IL-10 axes in thrombocytopenia associated with systemic lupus erythematosus: insights into the clinical paradox of antiphospholipid syndrome.

Mai A Abd-Elmawla, Olfat G Shaker, Marwa Mamdouh, Samer S Zekry, Shaymaa G Ibrahim, Gehan A Hegazy, Ghada Ayeldeen

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Mai A Abd-ElmawlaFaculty of Pharmacy, Department of Biochemistry, Cairo University, Kasr El Aini St., Cairo, 11562, Egypt. Mei.abdelmawla@pharma.cu.edu.eg.
Olfat G ShakerFaculty of Medicine, Department of Medical Biochemistry and Molecular Biology, Cairo University, Giza, 12613, Egypt.
Marwa MamdouhFaculty of Medicine, Department of clinical and chemical pathology, Fayoum University, Cairo, Egypt.
Samer S ZekryFaculty of Medicine, Department of Internal Medicine and Nephrology, Fayoum University, Cairo, Egypt.
Shaymaa G IbrahimFaculty of Pharmacy, Department of Biochemistry, Modern University for Technology and Information, Cairo, Egypt.
Gehan A HegazyFaculty of Medicine, Department of Clinical Biochemistry, King Abdulaziz University, Jeddah, Kingdom of Saudi Arabia.
Ghada AyeldeenFaculty of Medicine, Department of Medical Biochemistry and Molecular Biology, Cairo University, Giza, 12613, Egypt.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThrombocytopenia is a frequent haematological complication among SLE patients and ranges from asymptomatic to severe, which over time could progress into bleeding.

aimThe current study explored the role of PVT1/miR-181a as an upstream regulator of FOXP3/RORγt and their associated interleukins in the pathogenesis of SLE-associated thrombocytopenia, and coexistence of antiphospholipid antibodies.

methodsSixty SLE patients with thrombocytopenia and forty without thrombocytopenia, together with forty healthy controls were recruited, and blood samples were drawn. The gene expression of PVT1, miR-181a, FOXP3, and RORγt were measured using RT-PCR, whereas the serum concentrations of IL-23, IL-10, lipocalin2, and MMP9 were measured using ELISA.

resultsThe gene expression of miR-181a and RORγt were upregulated, PVT1 and FOXP3 were downregulated, levels of IL-23, lipocalin2, and MMP9 were increased, and IL-10 were lower among thrombocytopenic SLE patients relative to non-thrombocytopenic and healthy controls. Moreover, miR-181a and RORγt were upregulated, PVT1 and FOXP3 were downregulated, IL-23 level was increased, and IL-10 was decreased among thrombocytopenic SLE patients with positive antiphospholipid antibodies.

conclusionCollectively, PVT1/miR-181a could be an upstream regulator of RORγt/FOXP3 and their associated pro-inflammatory and anti-inflammatory markers IL-10/IL-23 in the pathogenesis of SLE-associated thrombocytopenia. These biomarkers in a panel could be valuable in supporting the diagnosis of thrombocytopenia. Furthermore, understanding the role of the PVT1/miR-181a and RORγt/FOXP3 axes could be valuable in underscoring the co-existence of thrombocytopenia and antiphospholipid syndrome, thus holding the potential for monitoring the progression of associated bleeding and thrombosis risk and tailoring therapeutic interventions.

Indexed as

Antiphospholipid SyndromeLupus Erythematosus, SystemicMicroRNAsNuclear Receptor Subfamily 1, Group F, Member 3RNA, Long NoncodingThrombocytopeniaAdultAntibodies, AntiphospholipidCase-Control StudiesFemaleForkhead Transcription FactorsHumansInterleukin-10Interleukin-23MaleMatrix Metalloproteinase 9Antibodies, AntiphospholipidForkhead Transcription FactorsFOXP3 protein, humanIL10 protein, humanInterleukin-10Interleukin-23Matrix Metalloproteinase 9MicroRNAsMIrn181 microRNA, humanNuclear Receptor Subfamily 1, Group F, Member 3PVT1 long-non-coding RNA, humanRNA, Long NoncodingRORC protein, humanAntiphospholipidLupusmiR-181aPVT1Thrombocytopenia

Identifiers

PMID42742767

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.